Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shervin Assassi

Showing results (61-70 of 238) with videos related to

Pageof 24
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 11, 2023
STAT6 suppression prevents bleomycin-induced dermal fibrosisJingjing Huang, Hydia Puente, Nancy E Wareing, et al.
Arthritis Care & Research|June 22, 2026
Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratificationAli Y Ayla, Meng Zhang, Bingrui Chen, et al.
Rheumatology (Oxford, England)|August 31, 2011
The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitisJennifer H Jang, Charles E Green, Shervin Assassi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2024
Unraveling the role of MiR-181 in skin fibrosis pathogenesis by targeting NUDT21Tingting W Mills, Minghua Wu, Jerry Alonso, et al.
The Journal of Rheumatology|July 3, 2018
KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung DiseaseGloria A Salazar, Masataka Kuwana, Minghua Wu, et al.
ACR Open Rheumatology|August 18, 2023
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory TherapyElizabeth R Volkmann, Holly Wilhalme, Shervin Assassi, et al.
The Journal of Rheumatology|August 3, 2016
Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic SclerosisSarada L Nandiwada, Lisa K Peterson, Maureen D Mayes, et al.
Arthritis and Rheumatism|November 30, 2006
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosisPravitt Gourh, Filemon K Tan, Shervin Assassi, et al.
Annals of the Rheumatic Diseases|February 22, 2022
Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung diseaseShervin Assassi, Elizabeth R Volkmann, W Jim Zheng, et al.
Arthritis Care & Research|February 13, 2013
Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?Xiaochun Liu, Maureen D Mayes, Claudia Pedroza, et al.
Pageof 24

Showing results (61-70 of 238) with videos related to

Sort By:
Pageof 24
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 11, 2023
STAT6 suppression prevents bleomycin-induced dermal fibrosisJingjing Huang, Hydia Puente, Nancy E Wareing, et al.
Arthritis Care & Research|June 22, 2026
Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratificationAli Y Ayla, Meng Zhang, Bingrui Chen, et al.
Rheumatology (Oxford, England)|August 31, 2011
The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitisJennifer H Jang, Charles E Green, Shervin Assassi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 9, 2024
Unraveling the role of MiR-181 in skin fibrosis pathogenesis by targeting NUDT21Tingting W Mills, Minghua Wu, Jerry Alonso, et al.
The Journal of Rheumatology|July 3, 2018
KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung DiseaseGloria A Salazar, Masataka Kuwana, Minghua Wu, et al.
ACR Open Rheumatology|August 18, 2023
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory TherapyElizabeth R Volkmann, Holly Wilhalme, Shervin Assassi, et al.
The Journal of Rheumatology|August 3, 2016
Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic SclerosisSarada L Nandiwada, Lisa K Peterson, Maureen D Mayes, et al.
Arthritis and Rheumatism|November 30, 2006
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosisPravitt Gourh, Filemon K Tan, Shervin Assassi, et al.
Annals of the Rheumatic Diseases|February 22, 2022
Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung diseaseShervin Assassi, Elizabeth R Volkmann, W Jim Zheng, et al.
Arthritis Care & Research|February 13, 2013
Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?Xiaochun Liu, Maureen D Mayes, Claudia Pedroza, et al.
Pageof 24